About Us
Fund
Support
Return
Our Companies
left
About Us
Our Companies
Our DNA
Fund
Our Investment Strategy
Our Investors
Our Funds
Our Charity Fund
Support
Our Value Creation
Our Team and Network
Return
Return to Investors
Return to People
Return to Society
right
News
JOIN OUR TEAM
Investor Portal
Contact
NEWS
Our Latest News
ARCHIMED’s sale of Polyplus to Sartorius Stedim earns 300x for MED I, an all-time record return for a private equity investment
View All
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
ARCHIMED invests in Title21 Health Solutions, a leading US-based healthcare software provider
July
12,
2022
ARCHIMED invests in Corealis Pharma, a North American CDMO, through MED III
May
24,
2022
ARCHIMED’s MED II fund earns a 6x return on EUROLyser, its first exit
May
9,
2022
ARCHIMED sells health ingredients developer Fytexia to Associated British Foods
February
2,
2022
ARCHIMED buys CARSO, a leader in purity testing for pharma and other industries
December
16,
2021
ARCHIMED reaches agreement to sell Bomi Group to UPS
December
16,
2021
<
1
2
3
4
5
…
13
>
368